NCT03454893View on ClinicalTrials.gov

Open Label, Study Of Efficacy and Safety Of AVR-RD-01 for Treatment-Naive Subjects With Classic Fabry Disease

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

February 21, 2018

Primary Completion Date

March 14, 2022

Study Completion Date

March 14, 2022

Conditions
Fabry Disease
Interventions
DRUG

AVR-RD-01

Single IV infusion of between 3 - 20 x 10\^6 CD34+ cells/kg.

Trial Locations (5)

15213

University of Pittsburgh Medical Center, Pittsburgh

07601

Hackensack University Medical Center, Hackensack

Unknown

Royal Melbourne Hospital, Melbourne

Royal Perth Hospital, Perth

Hospital de Clinicas de Porto Alegre, Porto Alegre

Sponsors

Lead Sponsor

AVROBIO
All Listed Sponsors
lead

AVROBIO

INDUSTRY

NCT03454893 - Open Label, Study Of Efficacy and Safety Of AVR-RD-01 for Treatment-Naive Subjects With Classic Fabry Disease | Biotech Hunter | Biotech Hunter